Diagnostic and Therapeutic Advances in Retinal Disease

Dear Colleagues,

Degenerative diseases of the retina continue to be a leading cause of vision loss, especially in an aging population. Although recent clinical advances, such as the use of inhibitors and blockers of various growth factors, have provided ophthalmologists with clinical tools of considerable efficacy, there is still a critical need for definitive treatments. Further advances in the treatment of retinal degeneration will require a deeper understanding of the molecular pathophysiology of these diseases. This Special Issue will promote this goal by highlighting notable advances in the diagnosis and therapy of retinal degenerative (RD) disease. In the area of retinal disease diagnosis, contributions are invited that feature innovations and advances in such areas as molecular diagnostics, imaging (especially applied to biomolecular detection), applications of artificial intelligence or informatics to assist in complex diagnoses, and innovative approaches that are based on multifactorial diagnostic indicators. Complementing the diagnostic aspects, this issue also invites contributions describing transformative and realistic cutting-edge approaches to the treatment of RD diseases, which have a potential to ameliorate RD, alleviate vision loss, and even restore sight. Gene therapies, neuroprotection, in vivo gene editing, retinal replacement, regeneration, immunomodulation, and therapeutic monoclonal antibody modalities to managing the RD diseases are all welcome in this Special Issue. Authors are requested to discuss the molecular, cellular, tissue or/and systemic mechanisms of therapies of the approaches outlined in each manuscript. 

Prof. Dr. Randolph D. Glickman
Dr. Igor O. Nasonkin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Cell therapy
• Degeneration
• Diagnosis
• Gene therapy
• Genome editing
• Neuroprotection
• Photoreceptor
• Regeneration
• Retina
• Retinal ganglion cells
• Retinal pigment epithelium
• Therapeutic antibodies
• Transplantation
• Vision restoration